Elizabeth Berry-Kravis

Dr. Elizabeth Berry-Kravis, MD, Ph.D. established the Fragile X Clinic and Research Program at Rush University Medical Center in Chicago in 1992, through which she provides care to over 700 patients with fragile X syndrome (FXS). Dr. Berry-Kravis has done extensive work in FXS and has expanded clinical translational work to other neurodevelopmental disorders and genetic neurodegenerative diseases including autism spectrum disorders. Her laboratory studies cellular roles of fragile X mental retardation protein (FMRP), its relationship to phenotypes, and optimization of genetic testing methods.

Dr. Berry-Kravis is a Professor of Pediatrics, Neurological Sciences, and Biochemistry at Rush University Medical Center in Chicago. She has studied medical issues, epilepsy, and psychopharmacology in FXS, and has been a leader in translational research in FXS including the development of outcome measures/biomarkers, natural history studies, newborn screening, and particularly clinical trials of new targeted treatments. Dr. Berry-Kravis has over 250 publications on genetic neurological diseases and is on several Advisory/Review Boards including those for the FRAXA Research Foundation and the National Fragile X Foundation (USA).

Dr. Berry-Kravis attended the University of Notre Dame for undergraduate studies and the University of Chicago for her MD/Ph.D. and training in Paediatric Neurology. Dr. Berry-Kravis has received numerous awards and recognition for her work including the FRAXA Champion Award, the American Academy of Neurology Sidney Carter Award in Child Neurology, the FRAXA Ingenuity Award, and the Child Neurology Society Denckla Award for her work in treatment translation for FXS and genetic cognitive disorders.